Moderna's stock rose 5% ahead of its earnings report, continuing a strong 685% gain this year, driven by its mRNA vaccine focus and oncology pipeline. Pfizer's shares fell 0.8% despite beating Q3 revenue estimates and raising its 2026 guidance, as COVID product sales declined but other drugs grew. Merck's stock dropped 2% after launching a new Phase 3 COPD trial, reflecting early-stage risk despite a 40% gain this year. Investors await Moderna's earnings to see if sales growth justifies its high valuation amid ongoing losses and cash burn.
Moderna leads with a strong price of USD 230.11 and a 4.20% gain on Pluang as of Nov 04, 2026 02:02 WIB, reflecting continued investor interest ahead of its earnings report. Pfizer trades lower at USD 30.41, down 0.85%, despite raised guidance, while Merck falls 2.54% to USD 144.59 amid new trial risks. These movements show active investor positioning on Pluang, where typical hold times range from 58 days for Moderna to 159 days for Pfizer.
